Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2862187 | 0.88 | PDE2A (0.32) | EPHX2PDE3BPDE3AP2RY12 | |
| SCHEMBL2869509 | 0.88 | MLYCD (0.37) | MLYCDEPHX2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3410897 | 0.86 | EPHX2 (0.34) | MLYCDEPHX2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2856847 | 0.86 | PDE3B (0.35) | MLYCDCYP3A4PDE3BPDE3AP2RY12 | |
| SCHEMBL2868488 | 0.84 | QPCT (0.35) | EPHX2 | |
| SCHEMBL2861338 | 0.83 | QPCT (0.37) | — | |
| SCHEMBL3409802 | 0.82 | MLYCD (0.43) | MLYCDEPHX2PDE3BPDE3AP2RY12 | |
| SCHEMBL2867143 | 0.81 | MAOB (0.35) | — | |
| SCHEMBL2861075 | 0.79 | EPHX2 (0.41) | MLYCDEPHX2PDE3BPDE3AP2RY12 | |
| SCHEMBL2865664 | 0.78 | EPHX2 (0.42) | MLYCDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370260-B1 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-11-24 | — | — | EP | claimed |
| US-7709510-B2 | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | claimed |
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | ME1, ME3, ME2 | MLYCD 4/4885EPHX2 1552/4885CYP3A4 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.